10568707 - GAU: 1648 Diwinge

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yosef YARDEN et al

Serial No.:

10/568,707

Filed:

December 14, 2006

For:

POLYNUCLEOTIDES, POLYPEPTIDES AND

ANTIBODIES AND USE THEREOF IN TREATING

TSG101-ASSOCIATED DISEASES

Examiner:

Not Yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 999999999999999

Group Art Unit: 1648

Attorney

Docket: 31570

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Marlin Q. Moynukin

Martin D. Moynihan

Registration No. 40,338

Dated: February 14, 2007

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to restand to a collection information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/568,707 INFORMATION DISCLOSURE December 14, 2006 Filing Date STATEMENT BY APPLICANT Yosef YARDEN et al First Named Inventor 1648 Art Unit (use as many sheets as necessary) Examiner Name Not yet Assigned Attorney Docket Number 31570 10 of Sheet U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Name of Patentee or **Publication Date** Document Number Examiner Cite Relevant Passages or Relevant Applicant of Cited Document MM-DD-YYYY Initials* No. Figures Appear Number-Kind Code² (if known)

		FOREIGN	PATENT DOC	UMENTS		\dashv
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	1	EP 0264166	04-20-1988	Gordon et al.		\vdash
	<u> </u>					\square
						+
				<u> </u>		+1
	<u> </u>		 			\Box
Examine Signatur	1	/Jeffrey Parkin/	1,	Date Considered	08/17/	2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ormation unless it contains a valid OMB control number.

Inder the Paperwe	ork Reduction	Act of 1995, no persons are required to respond to a collection of i	nformation unless it contains a valid	olete if Known					
	Sub	ostitute for form 1449A/PTO	Application Number	10/568,707					
I	NFOR	MATION DISCLOSURE	Filing Date	December 14, 2006	5				
-	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	t al				
		as many sheets as necessary)	Group Art Unit	1648					
	(use	as many sneets as necessary)	Examiner Name	Not yet Assigned					
Sheet	2	2 Of 10 Attorney Docket Number 31570							
		OTHER PRIOR ART – NON PATEN	IT LITERATURE DOCU	MEN IS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS)	title of the article (when approp	issue number(s)	Tr ²				
nitials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	2	Aizawa et al. "Kinesin Family in Murine Cer	ntral Nervous System", Th	e Journal of					
		Cell Biology 119(5): 1287-1296, 1992.	Cell Biology 119(5): 1287-1296, 1992.						
	3	Babst et al. "Mammalian Tumor Susceptibili	ty Gene 101 (TSG101) an	d the Yeast					
		Homologue, Vps23p, Both Function in Late	Endosomal Trafficking",	Traffic, 1: 248-					
		258, 2000.							
	4	Clavel et al. "Isolation of A New Human Reterovirus From West African Patients							
		With AIDS", Science, 233(4761): 343-346, 1986.							
	5	Cocchi et al. "Identification of RANTES, MIP-1a <e and="" as="" b>,="" mip-1b="" td="" the<=""></e>							
		Major HIV-Suppressive Factors Produced by CD8 ⁺ T Cells", Science,							
		270(5243): 1811-1815, 1995.							
-	6	Cole et al. "The EBV-Hybridoma Technique and Its Application to Human Lung							
		Cancer", Monoclonal Antibodies and Cancer Therapy, P.77-96, 1985.							
	7	Coruzzi et al. "Tissue-Specific and Light-Regulated Expression of A Pea Nuclear							
	j	Gene Encoding the Small Subunit of Ribulose-1,5-Bisphosphate Carboxylase", The							
		EMBO Journal, 3: 1671-1680, 1984.							
·	8	Cullen "RNA Interference: Antiviral Defense and Genetic Tool", Nature							
		Immunology 3(7): 597-599, 2002.							
2.0	9	Daar et al "High Concentrations of Recombinant Soluble CD4 Are Required to							
		Neutralize Primary Human Immunodeficiency Virus Type 1 Isolates", Proc. Natl.							
		Acad. Sci. USA, 87: 6574-6578, 1990.							
	10	Davies et al. "Selection of Specific Phage-Display Antibodies Using Libraries							
		Derived From Chicken Immunoglobulin Ge	nes", Journal of Immunol	ogical Methods,					
		186: 125-135, 1995.	· · · · · · · · · · · · · · · · · · ·	1 T-1-11-14- IIIV					
	11	Demirov et al. "Overexpression of the N-Te	rminal Domain of ISGIU	I Innibits HIV-					
		1 Budding by Blocking Late Domain Funct	ion", Proc. Nati. Acad. Sc	i. USA, 99(2):					
		955-960, 2002.	10 1 1 to Distinct	ingle Chain					
	12	Deng et al. "Basis for Selection of Improve	Carbonydrate-Binding S	ingle-Chain					
		Antibodies From Synthetic Gene Libraries"	, Proc. Nati. Acad. Sci. U.	SA, 92. 4992-					
		4996, 1995.	N V	With Improved					
	13	Deng et al. "Selection of Antibody Single-C	hain Variable Fragments	Chamistry					
		Carbohydrate Binding by Phage Display",	ne Journal of Biological	Chemisuy,					
		269(13): 9533-9538, 1994.	L - Dat Ingulia Conc. Evid	once for Role of					
	14	Edlund et al. "Cell-Specific Expression of t	ne kat insulin Gene: Evid	lements"					
		Two Distinct 5 ^{<font face="Symbol</td"><td>> 5%0</td>} Flanking E	> 5%0	icinciiis ,					
_		Science, 230(4728): 912-916, 1985.	la stidon de Duchos and	Inhhitore"					
	15	Englisch et al. "Chemically Modified Oligo	nucleotides as Probes and	2 1001					
		Angewandte Chemie, International Edition in English, 30(6): 613-722, 1991.							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including usering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperw	vork Reduction	Act of 1995, no persons are required to respond to a collection of in	nformation unless it contains a valid	OMB control number.					
	Sut	ostitute for form 1449A/PTO	Complete if Known						
			Application Number	10/568,707					
i		MATION DISCLOSURE	Filing Date	December 14, 200	06				
	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned					
Sheet	3	Of 10	Attorney Docket Number	31570					
Bilect	- -	OTHER PRIOR ART – NON PATEN		MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS),							
Initials	No.1	item (book, magazine, journal, serial symposium, cata publisher, city and/or coun	log, etc.) date, page(s), volume-		T ²				
	16	Erickson "Design and Structure of Symmetry	-Based Inhibitors of HIV	-1 Protease",					
		Perspectives in Drug Discovery and Design,	1: 109-128, 1993.						
	17	Erickson et al. "Design, Activity, and 2.8 A C			•				
		Symmetric Inhibitor Complexed to HIV-1 Pr. 1990.	otease", Science, 249(496	58): 527-533,					
	18	Fingl et al. ""Introduction. General Principles	", The Pharmacological I	Basis of					
	19	Therapeutics, Sec.I(Chap.1): 1-46, 1975.							
	19	Fishwild et al. "High-Avidity Human IgG? Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996.							
	20	Freed et al. "Viral Late Domains", Journal of Virology, 76(10): 4679-4687, 2002.							
	21	Gallo et al. "Frequent Detection and isolation of Cytopathic Retroviruses (HTLV-III)							
		From Patients With AIDS and at Risk for AIDS", Science, 224(4648): 500-503, 1984.							
	22	Garrus et al. "Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding", Cell, 107: 55-65, 2001.							
	23	Gewirtz "Oligonucleotide Therapeutics: Clot		nt Opinion in					
	124	Molecular Therapeutics, 1(3): 297-306, 1999 Giebel et al. "Screening of Cyclic Peptide Ph	ogo Librarias Idantifias I	igande That					
	24	Bind Strentavidin With High Affinities". Bio	age Libraries identifies L chemistry, 34: 15430-154	135, 1995.					
	25	Goila-Gaur et al. "Defects in Human Immuno	Bind Streptavidin With High Affinities", Biochemistry, 34: 15430-15435, 1995. Goila-Gaur et al. "Defects in Human ImmunodeficiencyVirus Budding and						
	-	Endosomal Sorting Induced by TSG101 Ove	rexpression", Journal of	Virology,					
		77(11): 6507-6519, 2003.							
	26	Grammatikakis et al. "P50cdc37 Acting in Concert With Hsp90 Is Required for Raf-1 Function", Molecular and Cellular Biology, 19(3): 1661-1672, 1999.							
1	27	Gurley et al. "Upstream Sequences Required for Efficient Expression of A Soybean							
	_ ,	Heat Shock Gene", Molecular and Cellular B	Biology, 6(2): 559-565, 19	86.					
	28	Guyader et al. "Genome Organization and Tr	ransaction and Transactiv	ation of the					
		Human Immunodeficiency Virus Type 2", N	ature, 326: 662-669, 1987	7.					
	29	Hammond et al. "Post-Transcriptional Gene		nded RNA",					
		Nature Reviews: Genetics, 2: 110-119, 2001	·						
	30	Hermida-Matsumoto et al. "Localization of l	luman Immunodeficiency	Virus Type 1					
		Gag and Env at the Plasma Membrane by Co	ontocal Imaging", Journal	of Virology,					
		74(18): 8670-8679, 2000.		1 0 11					
	31	Hicke "Protein Regulation by Monobiquitin"	', Nature Reviews: Molec	ular Cell					
		Biology, 2: 195-201, 2001.	II A -11 11 T1.	ama Crimeth adda					
	32	Hoogenboom et al. "By-Passing Immunisation	on, Human Antibodies Fr	om Synthetic					
		Repertoires of Germline VH Gene Segments	Kearranged in Vitro", Joi	ii iidi Oi					
1		Molecular Biology, 227: 381-388, 1992.							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the year of the reign of the Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperv	vork Reduction	Act of 1995, no persons are required to respond to a collection of in						
	Sul	bstitute for form 1449A/PTO		olete if Known				
	MEOD	MATION DIGGLOCUPE	Application Number	10/568,707				
		MATION DISCLOSURE	Filing Date	December 14, 2006				
	STATE	EMENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	t al			
	(use	as many sheets as necessary)	Group Art Unit	1648				
			Examiner Name	Not yet Assigned				
Sheet	4	Of 10	Attorney Docket Number	31570				
		OTHER PRIOR ART – NON PATEN						
Examiner	Cite	Include name of the author (in CAPITAL LETTERS),						
Initials	No.1	item (book, magazine, journal, serial symposium, cata publisher, city and/or coun	try where published.	` "	T ²			
	33	Hutv?gner et al. "RNAi: Nature Abhors A Do		oinion in				
		Genetics & Development, 12: 225-232, 2002.						
	34	Inbar et al. "Localization of Antibody-Combi						
		of Heavy and Light Chains", Proc. Natl. Acad						
	35	Joazeiro et al. "The Tyrosine Kinase Negative						
		E2-Dependent Ubiquitin-Protein Ligase", Sci						
	36	Joazeiro et al. "RING Finger Proteins: Mediators of Ubiquitin Ligase Activity", Cell,						
	37	102: 549-552, 2000. Jones et al. "Replacing the Complementarity-Determining Regions in A Human						
	"	Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.						
	38	Jones et al. "Improved Methods for Building Protein Models in Electron Density						
			tion of Errors in These Models", Acta Crystallographic					
		47(Part 2): 110-119, 1991.						
	39	Kahn et al. "The Safety and Pharmacokinetics of Recombinant Soluble CD4 (rCD4)						
		in Subjects With the Aquired Immunodeficient						
		Related Complex", Annals of Internal Medici						
	40	Katzmann et al. "Ubiquitin-Dependent Sorting Into the Multivesicular Body Pathway						
		Requires the Function oa A Conserved Endos						
		ESCRT-I", Cell, 106: 145-155, 2001.	_	•				
	41	Katzmann et al. "Receptor Downregulation a	nd Multivesicular-Body S	Sorting",				
		Nature Reviews: Molecular Cell Biology, 3:	893-905, 2002.					
	42	Khachigian "DNAzymes: Cutting A Path to A	New Class of Therapeur	tics", Current				
		Opinion in Molecular Therapeutics, 4(2): 119						
	43	Kikonyogo et al. "Proteins Related to the Nec	ld4 Family of Ubiquitin P	rotein Ligases				
		Interact With the L Domain of Rous Sarcoma	Virus and Are Required	for Gag				
		Budding From Cells", Proc. Natl. Acad. Sci.						
	44	Kraulis "MOLSCRIPT: A Program to Produc						
		Protein Structures", Journal of Applied Cryst						
	45	Kronenwett et al. "Oligodeoxyribonucleotide						
		Hematopoietic Cells Is Enhanced by Cationic		he				
		Hematopoietic Cell Subset", Blood, 91(3): 85	52-862, 1998.					
	46	Lam et al. "Rational Design of Potent, Bioava		c Ureas as HIV				
		Protease Inhibitors", Science, 263(5145): 380						
	47	Lange "Triple Combinations: Present and Fut						
·		Deficiency Syndromes and Human Retroviro						
	48	Larrick et al. "PCR Amplification of Antibod		ompanion to				
		Methods in Enzymology, 2(2): 106-110, 199	1.					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of		OMB control number.						
	Sut	bstitute for form 1449A/PTO	Application Number	10/568,707						
1	INEOD	MATION DISCLOSURE	<u> </u>		76					
			Filing Date	December 14, 200						
·	SIAIE	EMENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	et al					
	(use	as many sheets as necessary)	Group Art Unit	1648						
			Examiner Name	Not yet Assigned						
Sheet	5	Of 10	Attorney Docket Number	31570						
Blicci	+ -	OTHER PRIOR ART – NON PATEN								
Examiner	Cite	Include name of the author (in CAPITAL LETTERS)	, title of the article (when approp	riate), title of the						
Initials	No.1	publisher, city and/or cou	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	49	Lavigne et al. "Enhanced Antisense Inhibitor	n of Human Immunodefic	iency Virus						
		Type 1 in Cell Cultures by DLS Delivery Sy	stem", Biochemical and B	iophysical						
	 	Research Communications, 237: 566-571, 19	997.	4 . 11 . 4						
	50	Li et al. "Tsg101: A Novel Tumor Susceptib Homozygous Functional Knockout of Alleli	ollity Gene Isolated by Con	c" Cell 85:						
		319-329, 1996.	e Loci III Maiiiiiaiiaii Ceii	s , Cell, 65.						
	51	Li et al. "The TSG101 Tumor Susceptibility	Gene Is Located in Chron	nosome 11						
	31	Band P15 and Is Mutated in Human Breast (
	52	Lonberg et al. "Human Antibodies From Tra								
		Immunology, 13: 65-93, 1995.								
	53	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four								
		Distinct Genetic Modifications", Nature, 368: 856-859, 1994.								
	54	Luft "Clinical Implications. Making Sense Out of Antisense Oligodeoxynucleotide								
		Delivery: Getting There Is Half the Fun", Journal of Molecular Medicine, 76: 75-76,								
	 	1998.								
	55	Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies								
	56	by Chain Shuffling", Bio/Technology, 10: 779-783, 1992. Marks et al. "By-Passing Immunization. Human Antibodies From V-Gene Libraries								
	30	Displayed on Phage", Journal of Molecular Biology, 222: 581-597, 1991.								
	57	Martin-Serrano et al. "A Bipartite Late-Budding Domain in Human								
		Immunodeficiency Virus Type 1", Journal of Virology, 77(22): 12373-12377, 2003.								
	58	Martin-Serrano et al. "Role of ESCRT-I in Retroviral Budding", Journal of Virology,								
		77(8): 4794-4804, 2003.			<u></u>					
	59	Martin-Serrano et al. "HIV-1 and Ebola Virus Encode Small Peptide Motifs That								
		Recruit Tsg101 to Sites of Particle Assembl	y to Facilitate Egress", Na	ture Medicine,						
		7(12): 1313-1319, 2001.	iconucleotido Efficacy by	In Vitro						
	60	Matveeva et al. "Prediction of Antisense Oli		in vitro						
	61	Methods", Nature Biotechnology, 16: 1374- Mauro et al. "STI571: A Paradigm of new A	Agents for Cancer Therane	utics" Journal						
	01	of Clinical Oncology, 20(1): 325-334, 2002		uties , sournai						
	62	Mitsuya et al. "Molecular Targets for AIDS	Therapy", Science, 249(4	976): 1533-						
	"	1544, 1990.	, ,	ĺ						
	63	Mitsuya et al. "Targeted Therapy of Human	Immunodeficiency Virus	Related						
		Disease", The FASEB Journal, 5: 2369-238	1, 1991.							
	64	Morrison "Success in Specification", Nature	e, 368: 812-813, 1994.							
	65	Myers et al. "Tsg101, An Inactive Homolog	gue of Ubiquitin Ligase E2	, Interacts						
		Specifically With Human Immunodeficienc	y Virus Type 2 Gag Polyp	rotein and						
		Results in Increased Levels of Ubiquitinated	d Gag", Journal of Virolog	y, 76(22):						
		11226-11235, 2002.								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Olider the Laperw		Act of 1995, no persons are required to respond to a collection of		plete if Known					
	Sul	ostitute for form 1449A/PTO	Application Number	10/568,707					
]	INFOR	MATION DISCLOSURE	Filing Date	December 14, 200	4, 2006				
STATEMENT BY APPLICANT			First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
	(450	as many sneets as necessary)	Examiner Name	Not yet Assigned					
Sheet	6	Of 10	Attorney Docket Number	31570					
		OTHER PRIOR ART – NON PATER							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) item (book, magazine, journal, serial symposium, cal publisher, city and/or cou	alog, etc.) date, page(s), volume	issue number(s),	T ²				
_	66	Naldini et al. "Efficient Transfer, Integration		m Expression					
		of the Transgene in Adult Rat Brains Injecte							
		Acad. Sci. USA, 93: 11382-11388, 1996.		· 1					
	67	Neuberger "Generating High-Avidity Huma 14: 826, 1996.	n Mabs in Mice", Nature I	Biotechnology,					
	68		O'Bryan et al. "Mitogenesis and Endocytosis: What's at the INTERSECTION?",						
	69	Ott et al. "Retroviruses Have Differing Requirements for Proteasome Function in the							
		Budding Process", Journal of Virology, 77(6): 3384-3393, 2003.							
	70	Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole							
	' '	Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli",							
		Bio/Technology, 11: 1271-1277, 1993.							
-	71	Perelson et al. "HIV-1 Dynamics In Vivo: Virion Clearance Rate, Infected Cell Life-							
		Span, and Viral Generation Time", Science, 271(5255): 1582-1586, 1996.							
	72	Pinkert et al. "An Albumin Enhancer Located 10 Kb Upstream Functions Along With							
		Its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice",							
		Genes & Development, 1: 268-276, 1987.							
	73	Pornillos et al. "Mechanisms of Enveloped RNA Virus Budding", Trends in Cell							
		Biology, 12(12): 569-579, 2002.							
	74	Pornillos et al. "Structure of the Tsg101 UEV Domain in Complex With the PTAP							
		Motif of the HIV-1 P6 Protein", Nature Structural Biology, 9(11): 812-817, 2002.							
	75	Pornillos et al. "Structure and Functional Interactions of the Tsg101 UEV Domain",							
· · · · · ·		The EMBO Journal, 21(10): 2397-2406, 2002.							
	76	Porter "The Hydrolysis of Rabbit ?-Globulin and Antibodies With Crystalline							
		Papain", Biochemical Journal, 73: 119-126, 1959.							
	77	Presta "Antibody Engineering", Current Opi	nion in Structural Biology	, 2: 593-596,					
	70	1992.	****** ******* ***********************	C \$3.77.41 :1					
	78	Puffer et al. "Equine Infectious Anemia Viru							
		Late Assembly Domain of the Gag P9 Prote	in", Journal of Virology, /	1(9): 6541-					
	79	6546, 1997.	do Conjugatos for Efficien	t Dolivom, of					
	19	Rajur et al. "Covalent Protein-Oligonucleoti		L Delivery of					
	80	Antisense Molecules", Bioconjugate Chemis Riechmann et al. "Reshaping Human Antibo		222: 222 220					
	80	1988.	outes for Therapy, Nature	, 332: 323-329,					
	81	Davidkova et al. "Mechanism of Action of A	Inticance Oligodeovymuole	otides"					
	01	Antisense Research and Applications, CRC		tonues,					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Older the Paperw		Act of 1995, no persons are required to respond to a collection of in		olete if Known					
	Sut	ostitute for form 1449A/PTO	Application Number 10/568,707						
		MATION DISCLOSURE	Filing Date	December 14, 2006					
\$	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN et	al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned					
Sheet	7	Of 10	Attorney Docket Number	31570					
		OTHER PRIOR ART – NON PATEN	T LITERATURE DOCU	MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS),							
nitials	No.1	publisher, city and/or coun	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	82	Davidkova et al. "Pharmacological Inhibition		ense Research					
		and Applications, CRC Press, P.289-302, 199	93.						
	83	Santoro et al. "A General Purpose RNA-Clea	ving DNA Enzyme", Prod	c. Natl. Acad.					
		Sci. USA, 94: 4262-4266, 1997.							
	84	Schooley et al. "Recombinant Soluble CD4 T							
	ŀ		Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex", Annals of						
		Internal Medicine, 112: 247-253, 1990.							
	85	Schubert et al. "Augementation of Virus Secr	retion by the Human Imm	unodeficiency					
		Virus Type 1 Vpu Protein Is Cell Type Independent and Occurs in Cultured Human							
		Primary Macrophages and Lymphocytes", Journal of Virology, 69(12): 7699-7711, 1995.							
	86	Schubert et al. "Proteasome Inhibition Interferes With Gag Polyprotein Processing,							
		Release, and Maturation of HIV-1 and HIV-2", Proc. Natl. Acad. Sci. USA, 97(24): 13057-13062, 2000.							
	87	Sharp "RNA Interference - 2001", Genes & Development, 15: 485-490, 2001.							
	88	Smith et al. "Blocking of HIV-1 Infectivity by A Soluble, Secreted Form of the CD4							
		Antigen", Science, 238(4834): 1704-1707, 1987.							
	89	Studier et al. "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes",							
		Methods in Enzymology, 185(Chap.6): 60-89, 1990.							
	90	Takamatsu et al. "Expression of Bacterial Chloaramphenicol Acetyltransferase Gene							
		in Tobacco Plants Mediated by TMV-RNA", The EMBO Journal, 6(2): 307-311,							
		1987.							
	91	Teich et al. "Pathogenesis of Lentiviruses", RNA Tumor Viruses, CSH-Press,							
	İ	Chap. 14: 949-956, 1984.							
_	92	Tonkinson et al. "Antisense Oligodeoxynucleotides as Clinical Therapeutics Agents",							
		Cancer Investigation, 14(1): 54-65, 1996.							
	93	Tuschl "RNA Interference and Small Interference	ring RNAs", CHEMBIOC	CHEM, 2: 239-					
		245, 2001.							
	94	Tzahar et al. "A Hierarchical Network of Inte	erreceptor Interactions De	termines					
		Signal Transduction by Neu Differentiation l	Factor/Neuregulin and Ep	idermal					
		Growth Factor", Molecular and Cellular Bio	logy, 16(10): 5276-528 <u>7,</u>	1996.					
	95	Uno et al. "Antisense-Mediated Suppression	of Human Heparanase Go	ene Expression					
		Inhibits Pleural Dissemination of Human Ca	ncer Cells", Cancer Resea	arch, 61: 7855-					
		7860, 2001.	•						
	96	Varmus "Retroviruses", Science, 240(4858):	1427-1435, 1988.						
	97	Verhoeyen et al. "Reshaping Human Antiboo	dies: Grafting An Antilys	ozyme					
	1 '	Activity", Science, 239(4847): 1534-1536, 1	988.	-					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Olider the Faperw		Act of 1995, no persons are required to respond to a collection of i		plete if Known					
	Sut	ostitute for form 1449A/PTO	Application Number 10/568,707						
]	INFOR	MATION DISCLOSURE	Filing Date	December 14, 200	6				
i	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
	(, , , , , , , , , , , , , , , , , , ,	Examiner Name	Not yet Assigned					
Sheet	8	Of 10	Attorney Docket Number	31570					
Silect	-								
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), item (book, magazine, journal, serial symposium, cate publisher, city and/or cour	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	98		VerPlank et al. "Tsg101, A Homologue of Ubiquitin-Conjugating (E2) Enzymes, Binds the L Domain in HIV Type 1 Pr55 Gag", Proc. Natl. Acad. Sci. USA, 98(14):						
	99	Walton et al. "Prediction of Antisense Oligon Structured RNA Target", Biotechnology and							
	100	Wang et al. "Low Frequency of TSG101/CC Breast Cancers", Oncogene, 16: 677-679, 19	2 Gene Alterations in Inv	asive Human					
•	101	Waterman et al. "Molecular Mechanisms Un	Waterman et al. "Molecular Mechanisms Underlying Endocytosis and Sorting of ErbB Receptor Tyrosine Kinases", FEBS Letters, 490: 142-152, 2001.						
	102	Waterman et al. "The RING Finger of C-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor", The Journal of Biological Chemistry, 274(32): 22151-22154, 1999.							
	103	Rogers et al. "Gene Transfer in Plants: Production of Transformed Plants Using Ti Plasmid Vectors", Methods for Plant Molecular Biology, Academic Press, Sec.VIII(Chap.26-28): 423-463, 1988.							
	104	Weitzel et al. "Molecular Genetic Changes Associated With Ovarian Cancer", Gynecologic Oncology, 55: 245-252, 1994.							
	105	Welch etc. "Ribozyme Gene Therapy for Hepatitis C Virus Infection", Clinical and Diagnostic Virology, 10: 163-171, 1998.							
	106	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", Current Opinion in Biotechnology, 9: 486-496, 1998.							
-	107	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A Companion to Methods in Enzymology, 2(2): 97-105, 1991.							
	108	Wills et al. "Form, Function, and Use of Retroviral Gag Proteins", AIDS, 5: 639-654, 1991.							
	109	Wilson et al. "A Genetic Method for Defining DNA-Binding Domains: Application to the Nuclear Receptor NGFI-B", Proc. Natl. Acad. Sci. USA, 90: 9186-9190, 1993.							
	110	Winoto et al. "A Novel, Inducible and T Cel of the T Cell Receptor Alpha Locus", The E	Winoto et al. "A Novel, Inducible and T Cell-Specific Enhancer Located at the 3' End of the T Cell Receptor Alpha Locus", The EMBO Journal, 8(3): 729-733, 1989.						
	111	Wlodawer et al. "Structure-Based Inhibitors Biochemistry, 62: 543-585, 1993.	Wlodawer et al. "Structure-Based Inhibitors of HIV-1 Protease", Annual Reviews of						
	112	Yarchoan et al. Phase I Study of the Admini (rCD4) by Continuous Infusion to Patients V 5th International Conference on AIDS, Post P.564, 1989. Abstract.	Yarchoan et al. Phase I Study of the Administration of Recombinant Soluble CD4 (rCD4) by Continuous Infusion to Patients With AIDS or ARC", Proceedings of the 5th International Conference on AIDS, Poster Session, Basic Research, M.C.P.137,						
	113	Young "The Three-Dimensional Structures of Cryptococcus Neoformans and Its Complex Implications for the Identification of Peptide Biology, 274: 622-634, 1997.	With A Phage Display Li	ibrary:					
		Biology, 274. 022-034, 1777.							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nich indication of the document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ormation unless it contains a reliable of the
Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of in							
	Sub	ostitute for form 1449A/PTO		olete if Known					
_			Application Number	10/568,707					
		MATION DISCLOSURE	Filing Date	December 14, 200	06				
1	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned					
Sheet	9	Of 10	Attorney Docket Number	31570					
		OTHER PRIOR ART – NON PATEN							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), item (book, magazine, journal, serial symposium, cata publisher, city and/or coun	log, etc.) date, page(s), volume-	riate), title of the issue number(s),	T ²				
	114	Lai et al. "Differentiation of Hdm2-Mediated	P53 Ubiquitination and I	Idm2					
		Autoubiquitination Activity by Small Molecu							
		Acad. Sci. USA, 99(23): 14734-14739, 2002.							
	115	Aoki et al. "In Vivo Transfer Efficiency of A	ntisense Oligonucleotides	Into the					
		Myocardium Using HVJ-Liposome Method",	Biochemical and Biophy	sical Research					
		Communications, 231: 540-545, 1997.	Communications, 231: 540-545, 1997.						
	116	Jones et al. "Current Trends in Molecular Recognition and Bioseparation", Journal of							
<u> </u>		Chromatography A, 707: 3-22, 1995.							
	117	Banerji et al. "A Lymphocyte-Specific Cellular Enhancer Is Located Downstream of							
		the Joining Region in Immunoglobulin Heavy Chain Genes", Cell, 33: 729-740,							
<u> </u>		1983.							
	118	Barre-Sinoussi et al. "Isolation of A T-Lymphotrophic Retrovirus From A Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)", Science, 220(4599): 868-							
	119	871, 1983. Bernstein et al. "Role for A Bidentate Ribonuclease in the Initiation Step of RNA							
	119	Interference", Nature, 409: 363-366, 2001.							
	120	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242(4877): 423-426,							
	120	1988.							
	121	Bishop et al. "TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly							
	12.	and Are Recruited to VPS4-Induced Endosomes", The Journal of Biological							
		Chemistry, 276(15): 11735-11742, 2001.							
	122	Bitter et al. "Expression and Secretion Vectors for Yeast", Methods in Enzymology,							
		153(Chap.33): 516-544, 1987.							
	123	Blazevic et al. "Helper and Cytotoxic T Cell	Responses of HIV Type	1-Infected					
		Individuals to Synthetic Peptides of HIV Typ	e 1 Rev", AIDS Research	n and Human					
		Retroviruses, 11(11): 1335-1342, 1995.							
	124	Boerner et al. "Production of Antigen-Specif	ic Human Monoclonal Ai	ntibodies From					
		In Vitro-Primed Human Splenocytes", The Jo	ournal of Immunology, 14	4/(1): 80-95,					
	105	1991. Brantl "Antsense-RNA Regulation and RNA	Interference!! Dischimic	a at Biophysica					
	125		interference, Biochimic	a et Biophysica					
	126	Acta, 1575: 15-25, 2002. Breaker et al. "A DNA Enzyme With Mg2+I	Jenendent R.N.A. Dhospho	esterase					
	126	Activity", Chemistry & Biology, 2: 655-660,	zepenaeni Kiva riiospiio 1005	CSICI asc					
	127	Brisson et al. "Expression of A Bacterial Ger	ne in Plants by Using A. V	riral Vector".					
	127	Nature, 310: 511-514, 1984.	io in i faints by Osing A v	1141 70001 ,					
		14ature, 510. 511-514, 1504.							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of ir	Comp	olete if Known					
	Sut	ostitute for form 1449A/PTO	Application Number	10/568,707					
		MATION DISCLOSURE	Filing Date	December 14, 200)6				
;	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
	`	·	Examiner Name	Not yet Assigned					
Sheet	10	Of 10	Attorney Docket Number	31570					
		OTHER PRIOR ART – NON PATEN	T LITERATURE DOCU	MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS)	title of the article (when approp	riate), title of the	2				
Initials	No.1	item (book, magazine, journal, serial symposium, cata publisher, city and/or cour	itry where published.		T ²				
	128	Broglie et al "Light-Regulated Expression of	f A Pea Ribulose-1,5-Bisp	hosphate					
	1	Carboxylase Small Subunit Gene in Transfor	med Plant Cells", Science	e, 224(4651):					
	129	Byrne et al. "Multiplex Gene Regulation: A."	Two-Tiered Approach to	Transgene					
	12)	Regulation in Transgenic Mice", Proc. Natl.	Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477,						
	130	Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T							
	150	Cell Recentor Loci". Advances in Immunology, 43: 235-275, 1988.							
	131	Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human							
		Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation,							
		5: 281-285, 1998.							
	132	Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997.							
	133	Chang et al. "Analysis of TSG101 Tumour S	Susceptibility Gene Transc	cripts in					
		Cervical and Endometrial Cancers", British J. 1999.	Journal of Cancer, 79(3/4)): 445-450,					
									
					l				
				l l					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

/Jeffrey Parkin/

Signature

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperw	ork Reduction A	act of 1995, no persons are required to	respond to a collection of in	nformation unless it contains a valid	OMB control number.			
Substitute for form 1449A/PTO				Complete if Known				
_			***	Application Number	10/568,707			
		AATION DISCLOS		Filing Date	December 14, 200			
	STATE	MENT BY APPLIC	ANT	First Named Inventor	Yosef YARDEN e	et al		
	(use a	s many sheets as necessary	<i>'</i>)	Group Art Unit	1648			
				Examiner Name	Not yet Assigned			
Sheet	8		10	Attorney Docket Number	31570	· · · · · · · · · · · · · · · · · · ·		
		OTHER PRIOR AT	<u>RT – NON PATEN</u>	T LITERATURE DOCU	MENTS			
Examiner nitials	Cite No.1	item (book, magazine, journal	CAPITAL LETTERS), , serial symposium, cata blisher, city and/or cour	title of the article (when approlog, etc.) date, page(s), volume try where published.	riate), title of the -issue number(s),	T ²		
	98	VerPlank et al. "Tsg101, A	A Homologue of Ul	oiguitin-Conjugating (E2)	Enzymes,			
	120 /	Binds the L Domain in HI	V Type 1 Pr55 Gas	". Proc. Natl. Acad. Sci.	USA, 98(14):			
			iv Type I I I ou	,				
	7.724-7729, 2001. 99 Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A							
	99	Structured RNA Target"	Riotechnology and	Bioengineering 65(1): 1	-9, 1999.			
	Structured RNA Target", Biotechnology and Bioengineering, 65(1): 1-9, 1999. 100 Wang et al. "Low Frequency of TSG101/CC2 Gene Alterations in Invasive Human							
	100	Proof Cancers" Oncoger	ne 16: 677-679 19	98				
	Breast Cancers", Oncogene, 16: 677-679, 1998. Waterman et al. "Molecular Mechanisms Underlying Endocytosis and Sorting of							
	101	Waterman et al. "Molecular Mechanisms Underlying Endocytosis and Sorting of						
_ 	ErbB Receptor Tyrosine Kinases", FEBS Letters, 490: 142-152, 2001. Waterman et al. "The RING Finger of C-Cbl Mediates Desensitization of the							
	102	Waterman et al. "The RING Finger of C-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor", The Journal of Biological Chemistry, 274(32):						
	i i	22151-22154, 1999.						
	102	a to the property of the control of						
	Rogers et al. "Gene Transfer in Plants: Production of Transformed Plants Using 11 Plasmid Vectors", Methods for Plant Molecular Biology, Academic Press,							
]							
	- 	Sec.VIII(Chap.26-28): 423-463, 1988. Weitzel et al. "Molecular Genetic Changes Associated With Ovarian Cancer",						
	104	Weitzel et al. "Molecular	Genetic Changes F	associated with Ovarian	currect ,			
		Gynecologic Oncology, 55: 245-252, 1994.						
	105 /							
	105	Diagnostic Virology, 10: 163-171, 1998.						
	106	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target						
	105	RNA Levels", Current Opinion in Biotechnology, 9: 486-496, 1998.						
	107	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A						
		Companion to Methods in Enzymology, 2(2): 97-105, 1991.						
	108 /							
		1991.	14 1 1 C D C	- DNA Dinding Domain	as Application			
	109	Wilson et al. "A Genetic Method for Defining DNA-Binding Domains: Application						
		to the Nuclear Receptor NGFI-B", Proc. Natl. Acad. Sci. USA, 90: 9186-9190, 1993. Winoto et al. "A Novel, Inducible and T Cell-Specific Enhancer Located at the 3' End						
	110 /	Winoto et al. "A Novel, I	inducible and I Cel	MADO Taumal 8(2): 720	722 1080			
		of the T Cell Receptor A	ipna Locus, The E	- FILLY 1 Protocol Apr	vial Daviews of			
	111 /	Wlodawer et al. "Structu		of HIV-1 Protease, All	iuai Reviews 01			
		Biochemistry, 62: 543-58	85, 1993.	CD	Salubla CD4			
	112 /	Yarchoan et al. Phase I S	study of the Admin	Stration of Recombinant	coodings of the			
		(rCD4) by Continuous In	itusion to Patients	WITH AIDS OF ARC", Pro	h M C D 127			
		5th International Confere	ence on AIDS, Post	er Session, Basic Researc	лі, IVI.С.Г.137,			
		P.564, 1989. Abstract.	1.6	CA Delener de mide Dine	ling Antibody to			
	113	Young "The Three-Dime	ensional Structures	of A Polysaccharide Bind	ing Antibody to			
		Cryptococcus Neoforma	ns and its Complex	with A Phage Display L	Molocules			
		Implications for the Iden		e Milmotopes", Journal of	iviolecular			
	- 1	Biology, 274: 622-634,	1997.		-ti ifti- conformer			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

I ransiation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,